A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study

Neuro-Oncology

Volumn 8, Issue 2, 2006, Pages 189-193

  Prados, Michael D ^a   Lamborn, Kathleen ^a   Yung, W K A ^b   Jaeckle, Kurt ^b   Robins, H Ian ^c   Mehta, Minesh ^c   Fine, Howard A ^d   Wen, Patrick Y ^e   Cloughesy, Timothy ^f   Chang, Susan ^a   Nicholas, M Kelly ^a,l   Schiff, David ^g   Greenberg, Harry ^h   Junck, Larry ^h   Fink, Karen ^i,k   Hess, Ken ^b   Kuhn, John ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c University of Wisconsin Health   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

Clinical trial; Irinotecan; Phase 2; Recurrent malignant glioma

Indexed keywords

ANTICONVULSIVE AGENT; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; GLIOMA; GRANULOCYTOPENIA; HUMAN; MALE; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN TUMOR; DISEASE FREE SURVIVAL; EPILEPSY; MIDDLE AGED; MORTALITY; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; EPILEPSY; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33744477354     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2005-010     Document Type: Article

References (12)

1. Batchelor, T.T., Gilbert, M.R., Supko, J.G., Carson, K.A., Nabors, L.B., Grossman, S.A., Lesser, G.J., Mikkelsen, T., and Phuphanich, S. (2004) Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neura-Oncology 6, 21-27.
2. Buckner, J.C., Reid, J.M., Wright, K., Kaufmann, S.H., Erlichman, C., Ames, M., Cha, S., O'Fallon, J.R., Schaaf, L.J., and Miller, L.L. (2003) Irinotecan in the treatment of glioma patients: Current and future studies of the North Central Cancer Treatment Group. Cancer 97 (suppl.), 2352-2358.
3. Chamberlain, M.C. (2002) Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J. Neurooncol. 56, 183-188.
4. Cloughesy, T.F., Filka, E., Kuhn, J., Nelson, G., Kabbinavar, F., Friedman, H., Miller, L.L., and Elfring, G.L. (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97 (suppl.), 2381-2386.
5. Friedman, H.S., Petros, W.P., Friedman, A.M., Schaaf, LJ., Kerby, T., Lawyer, J., Parry, M., Houghton, P.J., Lovell, S., Rasheed, K., Cloughesy, T., Stewart, E.S., Colvin, O.M., Provenzale, J.M., McLendon, R.E., Bigner, D.D., Cokgor, I., Haglund, M., Rich, J., Ashley, D., Malczyn, J., Elfring, G.L., and Miller, L.L (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17, 1516-1525.
6. Gupta, E., Wang, X., Ramirez, J., and Rattain, M.J. (1997) Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother. Pharmacol. 39, 440-444.
7. Haaz, M.C., Riche, C., Rivory, L.P., and Robert, J. (1998) Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecine] by human hepatic microsomes. Drug. Metab. Dispos. 26, 769-774.
8. Hare, C.B., Elion, C.B., Houghton, P.J., Houghton, J.A., Keir, S., Marcelli, S.L., Bigner, D.D., and Friedman, H.S. (1997) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)- carbonyloxy-camptothecin against pediatric and adult central nervous System tumor xenografts. Cancer Chemother. Pharmacol. 39, 187-191.
9. Hess, K.R., Wong, E.T., Jaeckle, K.A., Kyritsis, A.P., Levin, V.A., Prados, M.D., and Yung, W.K.A. (1999) Response and progression in recurrent malignant glioma. Neuro-Oncology 1, 282-288.
10. Prados, M.D., Yung, W.K.A., Jaeckle, K.A., Robins, H.I., Mehta, M.P., Fine, H.A., Wen, P.Y., Cloughesy, T.F., Chang, S.M., Nicholas, M.K., Schiff, D., Greenberg, H.S., Junck, L., Fink, K.L., Hess, K.R., and Kuhn, J. (2004) Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-Oncology 6, 44-54.
11. Raymond, E., Fabbro, M., Boige, V., Rixe, O., Frenay, M., Vassal, G., Faivre, S., Sicard, E., Germa, C., Rodier, J.M., Vernillet, L., and Armand, J.P. (2003) Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann. Oncol. 14, 603-614.
12. Reid, J.M., Cha, S., Buckner, J.C., Petros, W.P., Friedman, H.S., Tourt-Uhlig, S., Walker, A., Kuhn, J.G., Prados, M., Supko, J.G., Gilbert, M.R., Batchelor, T.T., Schaaf, L., Gaylor, S.K., McGovren, J.P., and Gallo, J.M. (2001) Pharmacokinetics of CPT-11 in glioma patients: Pooled analysis of data from 4 NCI-sponsored trials. Clin. Cancer Res. 7 (suppl.), 373 (abstract 415).